An approximately twofold increase in AMPK activity, independent of the AMPK level or glycemia, was also shown in adipose tissue of patients with T2DM treated with metformin for 10 weeks compared with gliclazide therapy [104]. The gene discussed is PRKAA1; the disease is type 2 diabetes mellitus.